<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468376</url>
  </required_header>
  <id_info>
    <org_study_id>GLU-00-2010-1</org_study_id>
    <nct_id>NCT01468376</nct_id>
  </id_info>
  <brief_title>GLU-xx Formulations in Individuals With Impaired Glucose Tolerance</brief_title>
  <official_title>An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor company was acquired and new owner chose not to proceed with clinical study
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GLU-xx formulations</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>GLU-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-06</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-01</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-02</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-03</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-04</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-05</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-06</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-06</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy adults between 21-65 years of age

          -  Body Mass Index (BMI) between 25 and ≤40

          -  OGTT (75g glucola) peak value between ≥140mg/dl and ≤199 mg/dl at screening visit

          -  Willingness to adhere to the requirements of the protocol, including availability for
             follow-up visits and donation of blood samples

          -  Willingness and ability to sign written informed consent

          -  Women of child bearing capacity who agree to use an acceptable form of birth control
             during the trial [i.e., oral contraception, reliable use of a double-barrier method
             (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal
             ligation]

        Exclusion Criteria:

          -  Active diabetes mellitus [fasting blood glucose of ≥7.0 mmol/L (≥126 mg/dL) or ≥11.1
             mmol/L (≥200 mg/dL) after OGTT]

          -  Current coronary artery/ cardiovascular disease or history of a cardiovascular event
             (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary
             artery bypass grafting, angina pectoris) or have undergone a cardiovascular
             intervention within the past three months

          -  Seizure disorder

          -  Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men
             and less than 12 g/dL in women)

          -  Active infection, including HIV, hepatitis, etc

          -  Participants on Estrogen replacement must be on a stable dose for at least 3 months

          -  Serious illness requiring ongoing medical care or medication

          -  Gastrointestinal disorders or prior gastrointestinal surgeries (including gastric
             bypass or lap-band) that might cause complications or influence motility or satiety
             (e.g.,diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal
             narrowing or obstruction, difficulty swallowing)

          -  Any congenital spinal cord deformities or traumatic spinal cord injuries

          -  Uncorrected hypothyroidism

          -  Other significant metabolic endocrine disease

          -  Active liver disease or liver function impairment as evidenced by a history of liver
             disease or liver enzyme elevations &gt;three times the upper limit of normal

          -  Current cancer

          -  Significant kidney disease (calculated by eGFR &lt;60 mL/min)

          -  History or clinical manifestations of significant metabolic, hepatic, renal,
             hematological, pulmonary, cardiovascular, gastrointestinal, urological,
             neurological,or psychiatric disorders which in the opinion of the investigator would
             be expected to interfere with the study or increase risk to the subject

          -  Use of anticoagulants such as warfarin

          -  Use of medications that might affect weight or food absorption (e.g.,
             diuretics,glucocorticoids, anorexigenic agents, Orlistat, laxatives)

          -  Treatment within the previous 6 months with any medication that is known to affect
             glucose levels (such as insulin with or without an amylin analogue,
             sulfonylureas,meglitinides, biguanide metformin, thiazolidinediones, alpha-glucosidase
             inhibitors,oral dipeptidyl-peptidase-4 inhibitor, Sitagliptin, Incretin mimetic)

          -  Regular use of natural health products or dietary supplements known to affect glucose
             levels (such as chromium, zinc, fenugreek, cinnamon). If the participant agrees to
             stop taking these products 14 days prior to study entry and for the duration of the
             study, they can participate in the study

             o Any other natural health products or dietary supplements, with the exception of
             vitamins and minerals with dose of &lt; 600 mg/day of vitamin E and containing no vitamin
             K. Natural health products or dietary supplements include products such as, but not
             limited to, Echinacea, Ginseng, St. John's Wort, Gingko, Glucosamine, Fish Oil
             supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the
             form of pills, extracts, capsules, or tablets. If the participant agrees to stop
             taking these products 14 days prior to study entry and for the duration of the study,
             they can participate in the study

          -  Vegan or Vegetarian

          -  Pregnant or lactating women, or intending to become pregnant

          -  Known allergy to any ingredient in the study product

          -  Any significant auto-immune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Udani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicus Research LLC/Staywell Research LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staywell Research LLC</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>pre-diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

